PPARγ-agonists' renal effects

Minerva Urologica e Nefrologica

Volumn 57, Issue 4, 2005, Pages 247-260

  Izzedine, H ^a   Launay Vacher, V ^a   Buhaescu, I ^a   Heurtier, A ^a   Baumelou, A ^a   Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Diabetes mellitus; Diabetic nephropathy; PPAR ligands; Renal protection; Thiazolidinediones

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; INSULIN; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; BLADDER TUMOR; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION; GLUCOSE TOLERANCE; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY TUBULE; MACROPHAGE; MESANGIUM CELL; MICROALBUMINURIA; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PROTEIN LOCALIZATION; PROTEINURIA; RENAL PROTECTION; REVIEW; SCLEROSIS; VASODILATATION;

ANIMALS; CHROMANS; DIABETES MELLITUS; HEMODYNAMIC PROCESSES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 28544446410     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
2. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
3. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome Proliferator-Activated Receptor-2 Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes. The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002;51:2653-7.
4. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor 2 (PPAR2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010-3.
5. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for suscep-tibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 1998;47:821-30.
6. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999;42:1033-49.
7. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione(ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983;32:804-10.
8. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999;48:1415-24.
9. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-6.
10. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
11. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997;272:8071-6.
12. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997;273: F1013-22.
13. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-66.
14. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998;153:349-54.
15. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001;60:14-30.
16. rd et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-73.
17. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998;139:2748-54.
18. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998;47:810-4.
19. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981-3.
20. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-9.
21. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-50.
22. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272: E989-96.
23. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49: 1022-32.
24. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18 Suppl 2:523-9.
25. Bakris G, Viberti G, Weston WM, Heinse M, Porter LE, Freed MI. Rosiglitazone reduces renal urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003;17:7-12.
26. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complicat 2000;14:250-4.
27. Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, Imuta H et al. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 1999;128:673-83.
28. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 2002;18 Suppl 2:S16-22.
29. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999;145:333-40.
30. Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M, Hahnel B. A role for podocytes to counteract capillary wall distension. Kidney Int 1994;45:369-76.
31. Mundel P, Shankland SJ. Glomerular podocytes and adhesive interaction with glomerular basement membrane. Exp Nephrol 1999;7:160-6.
32. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000;58:137-43.
33. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-6.
34. Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 2000;1497:148-54.
35. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000;164: 1498-504.
36. Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL et al. Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 1996;50:1230-9.
37. Funk JO, Galloway DA. Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. Trends Biochem Sci 1998;23:337-41.
38. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11: 847-62.
39. Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int 1999;56: 1199-207.
40. Megyesi J, Price PM, Tamayo E, Safirstein RL. The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci U S A 1999;96:10830-5.
41. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002;51:403-8.
42. Tsuchiya T, Shimizu H, Shimomura K, Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol 2003;23:222-8.
43. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000;35:179-88.
44. Vaughan DE. Endothelial function, fibrinolysis, and angiotensin- converting enzyme inhibition. Clin Cardiol 1997;20 Suppl 2:II-34-7.
45. Fogo AB. Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 1999;7:147-59.
46. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-19.
47. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
48. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002.
49. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-16.
50. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49: 633-9.
51. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
52. Descheemaeker KA, Wyns S, Nelles L, Auwerx J, Ny T, Collen D. Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 1992;267:15086-91.
53. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
54. Border WA, Noble NA, Ketteler M. TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int Suppl 1995;49: S59-61.
55. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346:371-4.
56. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP Yang D et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 1996;50:745-53.
57. Kreisberg JI, Kreisberg SH. High glucose activates protein kinase C and stimulates fibronectin gene expression by enhancing a cAMP response element. Kidney Int Suppl 1995;51:S3-11.
58. van Goor H, Fidler V, Weening JJ, Grond J. Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids. Lab Invest 1991;64: 754-65.
59. van Goor H, van der Horst ML, Fidler V, Grond J. Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 1992;66:564-71.
60. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319-26.
61. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996;123: 227-34.
62. Shohat J, Boner G. Role of lipids in the progression of renal disease in chronic renal failure: evidence from animal studies and pathogenesis. Isr J Med Sci 1993;29: 228-39.
63. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated, receptor-gamma activators. Circulation 2000;101:235-8.
64. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
65. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000;267:345-9.
66. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998;95:7614-9.
67. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002;40:687-93.
68. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-905.
69. Panzer U, Schneider A, Guan Y, Reinking R, Zahner G, Harendza S et al. Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. Kidney Int 2002;62:455-64.
70. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
71. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
72. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-80.
73. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
74. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94: 1172-9.
75. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94: 2511-5.
76. Kotchen TA, Zhang HY, Reddy S, Hoffmann RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996;270:R660-6.
77. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-60.
78. Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 1989;257:F561-4.
79. Carmines PK, Fowler BC, Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 1993;265:F677-85.
80. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
81. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.
82. Sung BH, Izzo JI Jr, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999;34:83-8.
83. Kawasaki J, Hirano K, Nishimura J, Fujishima M, Kanaide H. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998;98:2446-52.
84. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46:433-9.
85. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998;11:1134-7.
86. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-302.
87. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
88. Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S et al. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 1997;61:455-64.
89. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998;247:353-6.
90. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem Biophys Res Commun 1999;254:757-63.
91. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 1994;24: 106-10.
92. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6.
93. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998;41:569-76.
94. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 1995;44:1105-9.
95. Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 2000;13:370-5.
96. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.
97. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 1993;21:1020-3.
98. Knock GA, Mishra SK, Aaronson PI. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 1999;368:103-9.
99. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20.
100. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-35.
101. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;6: 3452-6.
102. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999;33:798-806.
103. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809-17.
104. Fujiwara T, Ohsawa T, Takahashi S, Ikeda K, Okuno A, Ushiyama S et al. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sci 1998;63:2039-47.
105. Kurtz TW, Gardner DG. Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 1998;32:380-6.
106. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.
107. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000;102:1834-9.
108. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Sato K et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res 2001;24:229-33.
109. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→; S transition in vascular smooth muscle cells. J Biol Chem 2000;275:22435-41.
110. Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 2001;37:574-80.
111. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001;38:581-7.
112. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-34.
113. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19: 546-51.
114. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000;101:1311-8.
115. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999;48:1448-53.
116. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23.
117. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
118. Gorson DM. Significant weight gain with rezulin therapy. Arch Intern Med 1999;159:99.
119. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
120. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
121. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-4.
122. Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001;24:953-4.
123. Arid M, Ghana R, Lewington A, Brown J, Brunskill NJ. Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-gamma. J Am Soc Nephrol 2003;14:17-27.
124. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17: 1435-8.
125. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001;287:727-32.
126. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602.
127. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996;7:469-80.
128. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 1992;42: 647-56.
129. Wolf G. Molecular mechanisms of diabetic mesangial cell hypertrophy: a proliferation of novel factors. J Am Soc Nephrol 2002;13:2611-3.
130. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-99.